Impact of renal function on cardiovascular events in elderly hypertensive patients treated with efonidipine

Hypertension Research

Volumn 33, Issue 11, 2010, Pages 1211-1220

  Hayashi, Koichi ^a   Saruta, Takao ^a   Goto, Yoshio ^b   Ishii, Masao ^c  

^a KEIO UNIVERSITY   (Japan)

^b Japan Physician's Association   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Ca channel blockers; cardiovascular events; chronic kidney disease; elderly hypertension

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFONIDIPINE;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; AGED; AGING; ANGINA PECTORIS; ANTIHYPERTENSIVE THERAPY; AORTA DISSECTING ANEURYSM; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN HEMORRHAGE; BRAIN INFARCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC PATIENT; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; STROKE; SUBARACHNOID HEMORRHAGE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY DISEASES; MALE; MULTICENTER STUDIES AS TOPIC; NITROPHENOLS; ORGANOPHOSPHORUS COMPOUNDS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78149330595     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2010.162     Document Type: Article

References (44)

1. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36: 646-661.
2. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition a patient-level meta-analysis. Ann Intern Med 2003; 139: 244-252.
3. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, Maschio G, Brenner BM, Kamper A, Zucchelli P, Becker G, Himmelmann A, Bannister K, Landais P, Shahinfar S, de Jong PE, de Zeeuw D, Lau J, Levey AS. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87.
4. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996; 27: 1214-1218.
5. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 2000; 335: 827-838.
6. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
7. Ruilope LM, Salvetti A, Jamerson K, Hansson L, Warnold I, Wedel H, Zanchetti A. Renal function and intensive lowering of blood pressure in hypertensive participants of the hypertension optimal treatment (HOT) study. J Am Soc Nephrol 2001; 12: 218-225.
8. Eijkelkamp WB, Zhang Z, Brenner BM, Cooper ME, Devereux RB, Dahlöf B, Ibsen H, Keane WF, Lindholm LH, Olsen MH, Parving HH, Remuzzi G, Shahinfar S, Snapinn SM, Wachtell K, de Zeeuw D. Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. J Hypertens 2007; 25: 871-876.
9. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629-636.
10. Matsuo S, Imai E, Horio M, Yosuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H, Hishida A. Revised equations for estimating glomerular filtration rate (GFR) from serum creatinine in Japan. Am J Kidney Dis 2009; 53: 982-992.
11. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, Wakugawa Y, Hata J, Oishi Y, Shikata K, Yonemoto K, Hirakata H, Iida M. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int 2005; 68: 228-236.
12. JATOS Study Group. The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS): protocol, patient characteristics, and blood pressure during the first 12 months. Hypertens Res 2005; 28: 513-520.
13. Ishii M, Goto Y. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients. Hypertens Res 2008; 31: 2115-2127.
14. Japan Diabetes Society. Guide for the Treatment of Diabetes Mellitus. Bunkodo: Tokyo, 1999 (in Japanese).
15. Hata Y, Mabuchi H, Saito Y, Itakura H, Egusa G, Ito H, Teramoto T, Tsushima M, Tada N, Oikawa S, Yamada N, Yamashita S, Sakuma N, Sasaki J. Report of the Japan Atherosclerosis Society (JAS) Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese adults. J Atheroscler Thromb 2002; 9: 1-27.
16. Hayashi K, Ozawa Y, Fujiwara K, Wakino S, Kumagai H, Saruta T. Role of actions of calcium antagonists on efferent arterioles-with special references to glomerular hypertension. Am J Nephrol 2003; 23: 229-244.
17. Hayashi K, Nagahama T, Oka K, Epstein M, Saruta T. Disparate effects of calcium antagonists on renal microcirculation. Hypertens Res 1996; 19: 31-36.
18. Ozawa Y, Hayashi K, Nagahama T, Fujiwara K, Saruta T. Effect of T-type selective calcium antagonist on renal microcirculation: studies in the isolated perfused hydro-nephrotic kidney. Hypertension 2001; 38: 343-347.
19. Arima S, Kohagura K, Xu HL, Sugawara A, Abe T, Satoh F, Takeuchi K, Ito S. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
20. 2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342-353.
21. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL, Jones DW, Materson BJ, Oparil S, Wright Jr JT, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572. (Pubitemid 37430158)
22. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagarty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-1536.
23. Hayashi K, Kumagai H, Saruta T. Effects of efonidipine and ACE inhibitors on proteinuria in human hypertension with renal impairment. Am J Hypertens 2003; 16: 116-122.
24. Peterson JC, Adler S, Burkanrt JM, Greene T, Hebert LA, Hunsicker LG, King AJ, Klahr S, Massry SG, Seifter JL. Modification of Diet in Renal Disease Study Group: blood pressure control, proteinuria, and the progression of renal disease. Ann Intern Med 1995; 123: 754-762.
25. Wright Jr JT, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
26. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G. Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 2004; 164: 2459-2464.
27. 2+ channels with distinct inhibitory mechanisms. Pharmacology 2006; 78: 11-20.
28. v3.3(a1I)) expressed in Xenopus oocytes. Eur J Pharmacol 2009; 613: 100-107.
29. Fujiwara K, Kanno Y, Hayashi K, Takenaka T, Saruta T. Renal protective effects of efonidipine in partially nephrectomized spontaneously hypertensive rats. Clin Exp Hypertens 1998; 20: 295-312. (Pubitemid 28213250)
30. Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H. Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621-626.
31. Omae K, Ogawa T, Nitta K. Influence of T-calcium channel blocker treatment on deterioration of renal function in chronic kidney disease. Heart Vessels 2009; 24: 301-307.
32. Sugano N, Wakino S, Kanda T, Tatematsu S, Homma K, Yoshioka K, Hasegawa K, Hara Y, Suetsugu Y, Yoshizawa T, Hara Y, Utsunomiya Y, Tokudome G, Hosoya T, Saruta T, Hayashi K. T-type calcium channel blockade as a therapeutic strategy against renal injury in rats with subtotal nephrectomy. Kidney Int 2008; 73: 826-834.
33. 2+ channels with efonidipine decreased plasma aldosterone concentration in healthy volunteers. Hypertens Res 2006; 29: 493-497.
34. Tanaka T, Tsutamoto T, Sakai H, Fujii M, Yamamoto T, Horie M. Comparison of the effects of efonidipine and amlodipine on aldosterone in patients with hypertension. Hypertens Res 2007; 30: 691-697.
35. Hart P, Bakris GL. Calcium antagonists: do they equally protect against kidney injury? Kidney Int 2008; 73: 795-796.
36. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal disease. Kidney Int 2003; 63: 1468-1474. (Pubitemid 36350012)
37. Brantsma AH, Bakker SJ, de Zeeuw D, de Jong PE. Extended prognostic value of urinary albumin excretion for cardiovascular events. J Am Soc Nephrol 2008; 19: 1785-1791.
38. Agrawal B, Berger A, Wolf K, Luft FC. Microalbuminuria screening by reagent strip predicts cardiovascular risk in hypertension. J Hypertens 1996; 14: 223-228.
39. Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 2004; 43(Suppl 1): S1-1-S1-290.
40. Saruta T, Hayashi K, Ogihara T, Nakao K, Fukui T, Fukiyama K. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J study. Hypertens Res 2009; 32: 505-512.
41. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM. Albuminuria a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 2004; 110: 921-927.
42. Nakamura K, Okamura T, Hayakawa T, Kadowaki T, Kita Y, Ohnishi H, Saitoh S, Sakata K, Okayama A, Ueshima H. Chronic kidney disease is a risk factor for cardiovascular death in a community-based population in Japan-NIPPON DATA90. Circ J 2006; 70: 954-959.
43. Khan NA, Ma I, Thompson CR, Humphries K, Salem DN, Sarnak MJ, Levin A. Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 2006; 17: 244-253.
44. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, Newman AB, Sarnak MJ. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 2008; 168: 2212-2218.